Inhibrx Biosciences Shares Surge on Clinical Breakthrough

Inhibrx Biosciences US45720N1037

The stock of clinical-stage biopharmaceutical company Inhibrx Biosciences has experienced a dramatic ascent, appreciating by a remarkable 120 percent over a single month. This powerful rally is fueled by significant clinical trial successes for a key drug candidate, triggering a substantial upward revaluation of the company by the market.

The primary catalyst for the surge was announced on October 23, 2025. Inhibrx reported that its drug candidate, Ozekibart, successfully met all primary and secondary endpoints in a clinical study for chondrosarcoma. This outcome positions the therapy to potentially become a new standard of care for this rare form of cancer, representing a notable medical advancement.